IL22 and lung cancer: In general, blocking vascular cell adhesion molecule-1 (VCAM-1) by siRNA138 and inhibiting IL-22 with an anti-IL-22 antibody,137 CAF-CM-promoted proliferation was attenuated via factors downstream of PI3K/AKT signaling cascade in the same type of lung cancer.